Loading...
XSHE300601
Market cap2.30bUSD
Jan 16, Last price  
15.09CNY
1D
-0.40%
1Q
-17.36%
IPO
333.62%
Name

Shenzhen Kangtai Biological Products Co Ltd

Chart & Performance

D1W1MN
XSHE:300601 chart
P/E
19.59
P/S
4.85
EPS
0.77
Div Yield, %
1.19%
Shrs. gr., 5y
2.35%
Rev. gr., 5y
11.51%
Revenues
3.48b
+10.14%
122,499,033250,513,321303,363,797452,742,197551,940,9791,161,175,8112,016,902,8011,943,331,7532,261,177,3793,652,094,8963,157,401,7543,477,438,725
Net income
861m
11,447,9621,510,57331,162,58562,821,67986,213,538214,703,482435,685,115574,505,577679,186,1851,263,377,1120861,303,903
CFO
1.03b
+89.32%
5,252,60026,384,660112,059,069277,854,67378,323,552153,984,559336,476,192505,701,645439,847,4971,652,270,156545,695,9511,033,102,437
Dividend
Jun 14, 20240.2 CNY/sh
Earnings
May 30, 2025

Profile

Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined with live attenuated vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, and HIB conjugate vaccine. It has an agreement between YTB and Yong Tai Berhad in relation to the development and commercialization of Covid-19 inactivated vaccine in Malaysia. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.
URL
https://www.biokangtai.com/
IPO date
Feb 07, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,477,439
10.14%
3,157,402
-13.55%
Cost of revenue
2,411,876
2,446,362
Unusual Expense (Income)
NOPBT
1,065,562
711,040
NOPBT Margin
30.64%
22.52%
Operating Taxes
79,016
Tax Rate
7.42%
NOPAT
986,546
711,040
Net income
861,304
 
Dividends
(201,044)
(595,259)
Dividend yield
0.66%
1.71%
Proceeds from repurchase of equity
(100,992)
112,148
BB yield
0.33%
-0.32%
Debt
Debt current
60,043
273,683
Long-term debt
2,372,216
2,015,680
Deferred revenue
383,103
Other long-term liabilities
393,216
36,334
Net debt
1,136,662
(1,210,411)
Cash flow
Cash from operating activities
1,033,102
545,696
CAPEX
(718,451)
Cash from investing activities
(438,867)
Cash from financing activities
(418,054)
FCF
1,125,336
(25,780)
Balance
Cash
1,758,938
1,458,450
Long term investments
(463,340)
2,041,325
Excess cash
1,121,726
3,341,905
Stockholders' equity
6,451,054
5,797,607
Invested Capital
11,245,435
8,178,863
ROIC
10.16%
8.41%
ROCE
8.60%
6.16%
EV
Common stock shares outstanding
1,118,576
1,105,899
Price
27.15
-13.89%
31.53
-68.00%
Market cap
30,369,352
-12.90%
34,868,990
-68.14%
EV
31,506,014
33,658,579
EBITDA
1,266,953
911,988
EV/EBITDA
24.87
36.91
Interest
113,713
108,972
Interest/NOPBT
10.67%
15.33%